Baidu
map

ARCH PATHOL LAB MED:通过光谱组织病理学解决肺癌诊断中的差异

2019-02-06 MedSci MedSci原创

本研究报道了希望之城癌症中心(加利福尼亚州杜阿尔特)和CIRECALLC(马萨诸塞州剑桥市)之间合作肺癌研究的结果,该研究包括来自249名患者的328个样本,使用光谱组织病理学的光学技术(SHP)对这些样本进行组织分类。由于SHP基于物理测量,因此与基于评估细胞形态和组织结构的方法相比,它可在更客观和可重复的基础上进行诊断

该报告表明,SHP提供了可区别与肺鳞状细胞癌的腺癌,其准确性与免疫组织化学和腺鳞癌的高度可靠分类差不多。此外,该报告显示SHP可用于解决肺病理学中观察者之间的差异。光谱组织病理学是基于检测生化组成的变化而不是形态学特征,因此更类似于诸如基质辅助激光解吸电离飞行时间质谱成像的方法。基质辅助激光解吸电离飞行时间质谱和SHP成像模式都表明,在经典病理学中观察到的组织形态学特征的变化伴随着细胞水平的生化组成变化,并且可能与其相关。因此,这些成像方法提供了对疾病引起的生化变化的新见解。

原始出处:

Ali Akalin, Ayşegül Ergin, Resolving Interobserver Discrepancies in Lung Cancer Diagnoses by Spectral Histopathology

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1928818, encodeId=dcc61928818b2, content=<a href='/topic/show?id=71f1e771115' target=_blank style='color:#2F92EE;'>#组织病理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77711, encryptionId=71f1e771115, topicName=组织病理学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sun Dec 01 19:32:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786254, encodeId=7a0c1e8625475, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Apr 20 18:32:00 CST 2019, time=2019-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363922, encodeId=4880363922b5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8052578889, createdName=1259d912m97暂无昵称, createdTime=Mon Apr 01 13:25:08 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473471, encodeId=444f14e3471d2, content=<a href='/topic/show?id=4fd1e102257' target=_blank style='color:#2F92EE;'>#病理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71022, encryptionId=4fd1e102257, topicName=病理学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8ce7226273, createdName=jktdtl, createdTime=Fri Feb 08 12:32:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609555, encodeId=2102160955509, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 08 12:32:00 CST 2019, time=2019-02-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1928818, encodeId=dcc61928818b2, content=<a href='/topic/show?id=71f1e771115' target=_blank style='color:#2F92EE;'>#组织病理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77711, encryptionId=71f1e771115, topicName=组织病理学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sun Dec 01 19:32:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786254, encodeId=7a0c1e8625475, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Apr 20 18:32:00 CST 2019, time=2019-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363922, encodeId=4880363922b5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8052578889, createdName=1259d912m97暂无昵称, createdTime=Mon Apr 01 13:25:08 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473471, encodeId=444f14e3471d2, content=<a href='/topic/show?id=4fd1e102257' target=_blank style='color:#2F92EE;'>#病理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71022, encryptionId=4fd1e102257, topicName=病理学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8ce7226273, createdName=jktdtl, createdTime=Fri Feb 08 12:32:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609555, encodeId=2102160955509, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 08 12:32:00 CST 2019, time=2019-02-08, status=1, ipAttribution=)]
    2019-04-20 yb6560
  3. [GetPortalCommentsPageByObjectIdResponse(id=1928818, encodeId=dcc61928818b2, content=<a href='/topic/show?id=71f1e771115' target=_blank style='color:#2F92EE;'>#组织病理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77711, encryptionId=71f1e771115, topicName=组织病理学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sun Dec 01 19:32:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786254, encodeId=7a0c1e8625475, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Apr 20 18:32:00 CST 2019, time=2019-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363922, encodeId=4880363922b5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8052578889, createdName=1259d912m97暂无昵称, createdTime=Mon Apr 01 13:25:08 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473471, encodeId=444f14e3471d2, content=<a href='/topic/show?id=4fd1e102257' target=_blank style='color:#2F92EE;'>#病理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71022, encryptionId=4fd1e102257, topicName=病理学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8ce7226273, createdName=jktdtl, createdTime=Fri Feb 08 12:32:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609555, encodeId=2102160955509, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 08 12:32:00 CST 2019, time=2019-02-08, status=1, ipAttribution=)]
    2019-04-01 1259d912m97暂无昵称

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1928818, encodeId=dcc61928818b2, content=<a href='/topic/show?id=71f1e771115' target=_blank style='color:#2F92EE;'>#组织病理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77711, encryptionId=71f1e771115, topicName=组织病理学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sun Dec 01 19:32:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786254, encodeId=7a0c1e8625475, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Apr 20 18:32:00 CST 2019, time=2019-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363922, encodeId=4880363922b5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8052578889, createdName=1259d912m97暂无昵称, createdTime=Mon Apr 01 13:25:08 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473471, encodeId=444f14e3471d2, content=<a href='/topic/show?id=4fd1e102257' target=_blank style='color:#2F92EE;'>#病理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71022, encryptionId=4fd1e102257, topicName=病理学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8ce7226273, createdName=jktdtl, createdTime=Fri Feb 08 12:32:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609555, encodeId=2102160955509, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 08 12:32:00 CST 2019, time=2019-02-08, status=1, ipAttribution=)]
    2019-02-08 jktdtl
  5. [GetPortalCommentsPageByObjectIdResponse(id=1928818, encodeId=dcc61928818b2, content=<a href='/topic/show?id=71f1e771115' target=_blank style='color:#2F92EE;'>#组织病理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77711, encryptionId=71f1e771115, topicName=组织病理学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sun Dec 01 19:32:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786254, encodeId=7a0c1e8625475, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Apr 20 18:32:00 CST 2019, time=2019-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363922, encodeId=4880363922b5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8052578889, createdName=1259d912m97暂无昵称, createdTime=Mon Apr 01 13:25:08 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473471, encodeId=444f14e3471d2, content=<a href='/topic/show?id=4fd1e102257' target=_blank style='color:#2F92EE;'>#病理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71022, encryptionId=4fd1e102257, topicName=病理学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8ce7226273, createdName=jktdtl, createdTime=Fri Feb 08 12:32:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609555, encodeId=2102160955509, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 08 12:32:00 CST 2019, time=2019-02-08, status=1, ipAttribution=)]

相关资讯

Nat Med:肺癌早期诊断迎来新突破!有望在发病前就进行诊治

肺癌是全世界范围内,癌症致死的最主要原因之一。这一疾病之所以难治,很大一部分原因在于,患者在确诊时,病情已经进入了晚期。

中华医学会肺癌临床诊疗指南(2018版)

近年来,肺癌的诊断和治疗进展迅速。对于早期肺癌,人们日益追求精细且创伤性更小的手术方式;对于晚期肺癌,靶向治疗深入人心,免疫治疗的出现给野生型肺癌患者带来了新的希望,肺癌患者的治疗选择较前显著增多。为进一步提高我国肺癌的诊疗水平、改善患者的预后、给各级临床医师提供专业的循证医学意见,中华医学会组织全国的专家,整合近年来肺癌病理、基因检测、免疫分子标志物检测、新治疗手段等最新研究成果,并结合中国的国

Case Rep in Pulmono:原发性肺癌隐匿发展,低钠血症患者的非小细胞癌与小细胞癌并存

患者男性,66岁,有50年的吸烟史和严重的慢性阻塞性肺疾病(COPD),计算机断层扫描(CT)复查结果显示右上叶新发(RUL)肺结节和左下叶(LLL)慢性实变。患者肺功能检查(PFTS)显示气流阻塞,FEV1为2.58 L(81%预测)。6个月前的胸片上LLL实变明显,当地的肺科医生通过常规支气管镜活检检查该病灶,未发现恶性肿瘤的证据。

Lung Cancer:特异性97.9%,敏感性72.1%!吴一龙团队分析三项亚洲队列发现,通过FDA批准的液体活检可以作为肺癌组织检测的有力补充

2018年年末,我国肺癌领域的“大牛”吴一龙教授带领团队在Lung Cancer杂志上发表了一项研究[1],他们在三个亚洲人群队列中,对检测晚期非小细胞肺癌(NSCLC)患者表皮生长因子受体(EGFR)突变的COBAS®EGFR突变检测V2版在临床应用中的效果进行了评估。

JAMA:肺癌治疗后通过网络症状监测 vs 常规医院随访,哪个更优?

在一项单中心研究中,通过基于患者在网络上报告结果(PROs)对化疗期间的症状进行监测在之前已被证明可以延长生存期。一项多中心随机临床试验比较了网络监测和常规影像学检查分别用于检测肺癌患者在初始治疗后症状复发的效果比较。一项计划中的中期分析(9个月的随访)发现了显著的生存优势(PRO组生存期19个月vs对照组生存期12个月)。现在我们展示了最终的总体生存分析。如前述,在这个随机试验中, 晚期的IIA

Thorax:医院和专业服务对肺癌预后的影响

不同国家间提供的服务和劳动力仍存在差异。

Baidu
map
Baidu
map
Baidu
map